A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Tobramycin, Trough
Test CodeTOBRT
Alias/See Also
Epic: LAB38
Preferred Specimen
Specimen Type: Serum
Collection Container: Serum gel
Specimen Volume: 3 mL
Minimum Volume
0.25 mL
Other Acceptable Specimens
Collection Container: Red top
Instructions
- Draw blood no more than 30 minutes before next scheduled dose
- Centrifuge and separate cells after clot formation and within 4 hours of collection.
Transport Container
Plastic vial
Specimen Stability
Room temperature: Unacceptable
Refrigerated: 7 days
Frozen: 14 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Unlabeled, mislabeled, wrong tube type, hemolyzed, visually lipemic, QNS, exceeds specimen/stability requirements.
Methodology
Particle-enhanced turbidimetric inhibition immunoassay (PETINIA).
Setup Schedule
Daily
Report Available
Same day
Reference Range
Therapeutic: 0.2 – 2.0 µg/mL
Clinical Significance
The MULTIGENT Tobramycin assay is intended for the quantitative determination of tobramycin in human serum.
Tobramycin sulfate is an aminoglycoside antibiotic used to treat serious bacterial infections by intervening in the bacterial protein synthesis thereby killing the bacterium. Therapeutic serum levels vary depending on the microorganism involved and the patient's tolerance to the drug. The average half-life in patients with normal renal function is about 2-3 hours.
Monitoring serum levels of tobramycin decreases the frequency of serious toxic effects.
Tobramycin sulfate is an aminoglycoside antibiotic used to treat serious bacterial infections by intervening in the bacterial protein synthesis thereby killing the bacterium. Therapeutic serum levels vary depending on the microorganism involved and the patient's tolerance to the drug. The average half-life in patients with normal renal function is about 2-3 hours.
Monitoring serum levels of tobramycin decreases the frequency of serious toxic effects.
Performing Laboratory
Inova Laboratories
2832 Juniper Street
Fairfax, VA 22031
Last Updated: April 17, 2023
Last Review: N. Wolford, April 17, 2023